Pieris, Stelis ink anticalin development pact
Completing its second Indian deal this quarter, Pieris AG entered a pact with Stelis Biopharma Pvt. Ltd., a subsidiary of Bangalore-based Strides Arcolab Ltd., to develop two anticalin-based protein drugs, primarily for ophthalmology indications. Financial terms were not disclosed, but the deal has a similar structure to the partnership it entered in October with Zydus Cadila Ltd., of Ahmedabad.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter